Your browser doesn't support javascript.
loading
Sequence variants in malignant hyperthermia genes in Iceland: classification and actionable findings in a population database.
Fridriksdottir, Run; Jonsson, Arnar J; Jensson, Brynjar O; Sverrisson, Kristinn O; Arnadottir, Gudny A; Skarphedinsdottir, Sigurbjorg J; Katrinardottir, Hildigunnur; Snaebjornsdottir, Steinunn; Jonsson, Hakon; Eiriksson, Ogmundur; Oskarsson, Gudjon R; Oddsson, Asmundur; Jonasdottir, Adalbjorg; Jonasdottir, Aslaug; Sigurdsson, Gisli H; Indridason, Einar P; Sigurdsson, Stefan B; Bjornsdottir, Gyda; Saemundsdottir, Jona; Magnusson, Olafur T; Bjornsson, Hans T; Thorsteinsdottir, Unnur; Sigurdsson, Theodor S; Sulem, Patrick; Sigurdsson, Martin I; Stefansson, Kari.
Afiliação
  • Fridriksdottir R; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Jonsson AJ; Division of Anaesthesia and Intensive Care, Landspitali University Hospital, Reykjavik, Iceland.
  • Jensson BO; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Sverrisson KO; Division of Anaesthesia and Intensive Care, Landspitali University Hospital, Reykjavik, Iceland.
  • Arnadottir GA; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Skarphedinsdottir SJ; Division of Anaesthesia and Intensive Care, Landspitali University Hospital, Reykjavik, Iceland.
  • Katrinardottir H; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Snaebjornsdottir S; Division of Anaesthesia and Intensive Care, Landspitali University Hospital, Reykjavik, Iceland.
  • Jonsson H; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Eiriksson O; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Oskarsson GR; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Oddsson A; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Jonasdottir A; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Jonasdottir A; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Sigurdsson GH; Division of Anaesthesia and Intensive Care, Landspitali University Hospital, Reykjavik, Iceland.
  • Indridason EP; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Sigurdsson SB; Division of Anaesthesia and Intensive Care, Landspitali University Hospital, Reykjavik, Iceland.
  • Bjornsdottir G; School of Health Sciences, University of Akureyri, Akureyri, Iceland.
  • Saemundsdottir J; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Magnusson OT; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Bjornsson HT; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Thorsteinsdottir U; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Sigurdsson TS; Department of Genetics and Molecular Medicine, Landspitali University Hospital, Reykjavik, Iceland.
  • Sulem P; McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, MD, USA.
  • Sigurdsson MI; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Stefansson K; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Eur J Hum Genet ; 29(12): 1819-1824, 2021 12.
Article em En | MEDLINE | ID: mdl-34462577
Malignant hyperthermia (MH) susceptibility is a rare life-threatening disorder that occurs upon exposure to a triggering agent. MH is commonly due to protein-altering variants in RYR1 and CACNA1S. The American College of Medical Genetics and Genomics recommends that when pathogenic and likely pathogenic variants in RYR1 and CACNA1S are incidentally found, they should be reported to the carriers. The detection of actionable variants allows the avoidance of exposure to triggering agents during anesthesia. First, we report a 10-year-old Icelandic proband with a suspected MH event, harboring a heterozygous missense variant NM_000540.2:c.6710G>A r.(6710g>a) p.(Cys2237Tyr) in the RYR1 gene that is likely pathogenic. The variant is private to four individuals within a three-generation family and absent from 62,240 whole-genome sequenced (WGS) Icelanders. Haplotype sharing and WGS revealed that the variant occurred as a somatic mosaicism also present in germline of the proband's paternal grandmother. Second, using a set of 62,240 Icelanders with WGS, we assessed the carrier frequency of actionable pathogenic and likely pathogenic variants in RYR1 and CACNA1S. We observed 13 actionable variants in RYR1, based on ClinVar classifications, carried by 43 Icelanders, and no actionable variant in CACNA1S. One in 1450 Icelanders carries an actionable variant for MH. Extensive sequencing allows for better classification and precise dating of variants, and WGS of a large fraction of the population has led to incidental findings of actionable MH genotypes.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: População / Mutação de Sentido Incorreto / Frequência do Gene / Hipertermia Maligna Tipo de estudo: Diagnostic_studies Limite: Adult / Child / Female / Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: População / Mutação de Sentido Incorreto / Frequência do Gene / Hipertermia Maligna Tipo de estudo: Diagnostic_studies Limite: Adult / Child / Female / Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article